Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 80 (1), 80-88
- https://doi.org/10.1016/j.jaad.2018.06.046
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspectiveAnnals Of The Rheumatic Diseases, 2012
- Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled studyArthritis & Rheumatism, 2012
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialThe Lancet, 2012
- Hidradenitis SuppurativaNew England Journal of Medicine, 2012
- Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo studyBritish Journal of Dermatology, 2011
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativaBritish Journal of Dermatology, 2011
- Breaking Free of Sample Size Dogma to Perform Innovative Translational ResearchScience Translational Medicine, 2011
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010
- Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 InhibitorJournal of Pharmacology and Experimental Therapeutics, 2004
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994